Brief: MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin

Morphosys AG

30/01/2024 07:54

Jan 30 (Reuters) - MORPHOSYS AG  MORG.DE :
    * REPORTS PRELIMINARY 2023 MONJUVI U.S. NET PRODUCT SALES
AND
GROSS MARGIN, PROVIDES 2024 FINANCIAL GUIDANCE AND REDUCES
FINANCIAL LIABILITY
    * MORPHOSYS AG - PRELIMINARY 2023 MONJUVI U.S. NET PRODUCT
SALES
OF US$ 92.0 MILLION (EUR 85.0 MILLION)
    * MORPHOSYS AG - ANTICIPATED 2024 MONJUVI U.S. NET PRODUCT
SALES
IN RANGE OF US$ 80 TO 95 MILLION
    * MORPHOSYS AG - ANTICIPATED 2024 MONJUVI U.S. NET PRODUCT
SALES
IN RANGE OF US$ 80 TO 95 MILLION
    * MORPHOSYS AG - ANTICIPATED 2024 OPEX IN RANGE OF EUR 350
TO 380
MILLION AND 2024 CASH BURN OF APPROXIMATELY EUR 250 MILLION
(EXCLUDING DEBT AND INTEREST PAYMENTS)
    * MORPHOSYS AG - PRELIMINARY UNAUDITED FINANCIAL LIABILITY
FROM
COLLABORATION WITH INCYTE OF APPROXIMATELY EUR 114 MILLION,
REPRESENTING A REDUCTION OF EUR 112 MILLION
    * MORPHOSYS AG - ANTICIPATED 2024 OPEX IN RANGE OF EUR 350
TO 380
MILLION AND 2024 CASH BURN OF APPROXIMATELY EUR 250 MILLION
(EXCLUDING DEBT AND INTEREST PAYMENTS)
    * MORPHOSYS AG - FOR FULL YEAR OF 2024, MORPHOSYS EXPECTS
MONJUVI
U.S. NET PRODUCT SALES IN RANGE OF US$ 80 TO 95 MILLION
    * MORPHOSYS AG - FURTHER, PRELIMINARY 2023 GROSS MARGIN FOR
MONJUVI U.S. NET PRODUCT SALES IS 69%
    * MORPHOSYS AG - WITH ALL OF MORPHOSYS' PHASE 3 CLINICAL
PROGRAMS
NOW FULLY ENROLLED AND ADDITIONAL COST OPTIMIZATION MEASURES
PLANNED, MORPHOSYS' ANTICIPATED 2024 OPERATING EXPENSES ARE
EXPECTED TO BE LOWER COMPARED TO 2023
    * MORPHOSYS AG - AS A RESULT, COMPANY EXPECTS AN ANTICIPATED
2024
CASH BURN OF APPROXIMATELY EUR 250 MILLION (EXCLUDING DEBT AND
INTEREST PAYMENTS)
    * MORPHOSYS AG - ANTICIPATED 2024 OPERATING EXPENSES ARE
EXPECTED
TO BE LOWER COMPARED TO 2023 (ADDS DROPPED FIGURE)

Source text for Eikon:  ID:nEQbtHqxBa 
Further company coverage:  MORG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))